Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Ellence: Breast cancer (adjuvant) after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

ELLENCE is an anthracycline topoisomerase inhibitor indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer ( 1 ).

Broader topic: Breast Cancer

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
adjuvant
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      following resection of primary breast cancer ( 1 )
      status
      required
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for Ellence (product label). Only dimensions stated in that wording are part of this definition.
    source wording
    ELLENCE is an anthracycline topoisomerase inhibitor indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer ( 1 ).

    Study evidence for this setting

    0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice